id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
65,,,,,,,,,,,,,,,2024-05-07T12:46:15+06:00,BSH - H12112213760,Left,Eribulin,2023-06-27,1.0,"Review from TMH, Mumbai, Started ADCT at India With EC on 22.11.21. Cycle 4 completed on 3.02.21, Cycle
8 with Paclitaxel due on 01.05.2022> On Tamoxifen since May- Oct (2022)> PD with pleural effusion.
Review from TMH, Mumbai, Started 2nd line Gemcitabin 1900mg + Carboplatin 250mg (D1,8 q3w) C1D1
from 10.01.2023 after evaluation from TMH> Cycle 3 Day 8 completed on 2.03.23, Review from TMH and
started C4D1 28.03.2023, C6 completed on 27/05.2023 Metronomic therapy Capecitabine as per india for C4D8 then reviewed > PD> Switched to Inj Eribulin",2023-06-05,,2024-01-09,,2023-06-05,,,Breast,61,Upper class,BSBSC-240000061,DR. FARZANA AKTER,1731214924,1986-12-27,Female,,,,,Prof Dr Qamruzzaman Chowdhury,BSH,2.0,Switch Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,"C50.9- Breast, unspecified",Breast,Left,,,Progressed,Alive,PD,,,,,,,,,,,,,,,,,,,,,
